Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPPORT long-term open-label secukinumab study in noninfectious posterior segment uveitis
2010-021239-15Phase 3Terminated
- Sponsor
- Novartis
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of secukinumab in non-infectious posterior uveitis (NIPU) and non-infectious panuveitis (NIU), sponsored by Novartis. Primary endpoints: Long-term safety data collection and Clinically active posterior segment uveitis after treatment withdrawal. Started Sep 2010; status: terminated.
02
Drugs
secukinumab
03
Conditions
non-infectious posterior uveitis (NIPU)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on 2010-021239-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021239-15.